Peter Goodhand is a leader in the global health sector, holding senior executive and board member positions in the health research advancement community
He currently serves as the Chief Executive Officer of the Global Alliance for Genomics in health and played a key role in its creation. Mr. Goodhand has served as President of the Ontario Institute for Cancer Research (OICR) and President and CEO of the Canadian Cancer Society. Before joining the charitable sector, Goodhand had a 20 year career in the global medical technology industry, including strategic leadership roles with multinational healthcare companies such as American Cyanamid and Johnson & Johnson and as the founding Managing Director of the Health Technology Exchange (HTX).
Goodhand is currently Co-Chair of the Medical and Scientific Advisory Board of Global Genes, Co-Chair of the International 100K+ Cohorts Consortium (IHCC), member of the Global Genomic Medicine Collaboration (G2MC) Steering Committee, member of the Ethical and Scientific Advisory Board of EUCANCan, board director of Rare X, member of advisory committee for the Secure Platform for Health and Genomics, a member of the Advisory Committee for Genome Canada’s All for One rare disease initiative and a member of the Occupational Cancer Research Centre Steering Committee.
